Clinical Trial Update: Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 window study comparing amcenestrant (SAR439859) to letrozole in postmenopausal ER-positive, HER2-negative breast cancer was terminated. Results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• amcenestrant (SAR439859) (amcenestrant)

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-06-29